Evidence map›Paper›PMID 31921404›Full record

ArticleMolecular autism2020

TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and rapamycin-induced MNK-eIF4E signaling.

Pauline Martin, Vilas Wagh, Surya A Reis, Serkan Erdin, Roberta L Beauchamp, Ghalib Shaikh, Michael Talkowski, Elizabeth Thiele, Steven D Sheridan, Stephen J Haggarty and 1 more

Open access · goldAbstract read
In one paragraph

Article in Molecular autism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Pauline Martin1Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114 USA.
Vilas Wagh2MERCK Research Laboratories, Boston, MA 02115 USA.
Surya A Reis1Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114 USA.
Serkan Erdin1Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114 USA.
Roberta L Beauchamp1Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114 USA.
Ghalib Shaikh1Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114 USA.
Michael Talkowski1Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114 USA.
Elizabeth Thiele3Department of Neurology, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114 USA.
Steven D Sheridan1Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114 USA.
Stephen J Haggarty1Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114 USA.
Vijaya Ramesh1Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114 USA.
Massachusetts General Hospital · USMerck & Co., Inc., Rahway, NJ, USA (United States) · US

Funding

Tuberous Sclerosis Complex Patients iPSC-derived NPCs and NCCs as Human Model Systems to Identify Novel TargetsR01NS109540 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI HAGGARTY, STEPHEN J, RAMESH, VIJAYA · 2019 to 2023
$2.5M
NINDS NIH HHS R01 NS109540
6 · The paper itself

Abstract

Background: Tuberous sclerosis complex (TSC) is a neurodevelopmental disorder with frequent occurrence of epilepsy, autism spectrum disorder (ASD), intellectual disability (ID), and tumors in multiple organs. The aberrant activation of mTORC1 in TSC has led to treatment with mTORC1 inhibitor rapamycin as a lifelong therapy for tumors, but TSC-associated neurocognitive manifestations remain unaffected by rapamycin. Methods: Here, we generated patient-specific, induced pluripotent stem cells (iPSCs) from a TSC patient with a heterozygous, germline, nonsense mutation in exon 15 of Results: Differentiated NPCs revealed enlarged cell size in TSC1-Het and Null NPCs, consistent with mTORC1 activation. TSC1-Het and Null NPCs also revealed enhanced proliferation and altered neurite outgrowth in a genotype-dependent manner, which was not reversed by rapamycin. Transcriptome analyses of TSC1-NPCs revealed differentially expressed genes that display a genotype-dependent linear response, i.e., genes upregulated/downregulated in Het were further increased/decreased in Null. In particular, genes linked to ASD, epilepsy, and ID were significantly upregulated or downregulated warranting further investigation. In TSC1-Het and Null NPCs, we also observed basal activation of ERK1/2, which was further activated upon rapamycin treatment. Rapamycin also increased MNK1/2-eIF4E signaling in TSC1-deficient NPCs. Conclusion: MEK-ERK and MNK-eIF4E pathways regulate protein translation, and our results suggest that aberrant translation distinct in TSC1/2-deficient NPCs could play a role in neurodevelopmental defects. Our data showing upregulation of these signaling pathways by rapamycin support a strategy to combine a MEK or a MNK inhibitor with rapamycin that may be superior for TSC-associated CNS defects. Importantly, our generation of isogenic sets of NPCs from TSC patients provides a valuable platform for translatome and large-scale drug screening studies. Overall, our studies further support the notion that early developmental events such as NPC proliferation and initial process formation, such as neurite number and length that occur prior to neuronal differentiation, represent primary events in neurogenesis critical to disease pathogenesis of neurodevelopmental disorders such as ASD.

Indexed as

Tuberous SclerosisCodon, NonsenseCRISPR-Cas SystemsEukaryotic Initiation Factor-4EGene EditingGerm-Line MutationHumansInduced Pluripotent Stem CellsIntracellular Signaling Peptides and ProteinsMechanistic Target of Rapamycin Complex 1Neural Stem CellsNeurogenesisPhenotypeProtein Serine-Threonine KinasesRNA-SeqSignal TransductionCodon, NonsenseEukaryotic Initiation Factor-4EIntracellular Signaling Peptides and ProteinsMechanistic Target of Rapamycin Complex 1MKNK1 protein, humanProtein Serine-Threonine KinasesSirolimusTSC1 protein, humanTuberous Sclerosis Complex 1 ProteinCRISPR/Cas9Disease modelingEarly neurodevelopmentInduced pluripotent stem cellsMEK-ERK1/2MNK1/2-eIF4EmTORC1Neural progenitor cellsTSC1Tuberous sclerosis complex

Identifiers

PMID31921404
PMCPMC6945400
OpenAlexW3000723171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.